

1 **Title: 90K/LGALS3BP Expression is Upregulated in COVID-19 but Does Not**
2 **Restrict SARS-CoV-2 Infection**

3 Laure Bosquillon de Jarcy^{1,2,3}, Bengisu Akbil^{1,2}, Johanna Leyens¹, Dylan Postmus^{1,2}, Greta
4 Harnisch¹, Jenny Jansen¹, Marie L. Schmidt¹, Annette Aigner⁴, Fabian Pott^{1,2}, Robert Lorenz
5 Chua⁵, Lilian Krist⁶, Roberta Gentile⁷, Barbara Mühlemann¹, Terry C. Jones^{1,8}, Daniela
6 Niemeyer^{1,9}, Julia Fricke⁶, Thomas Keil^{6,10,11}, Tobias Pischon^{12,13,14,15}, Jürgen Janke¹³,
7 Christian Conrad⁵, Stefano Iacobelli⁷, Christian Drosten^{1,9}, Victor M. Corman^{1,9}, Markus
8 Ralser^{16,17}, Roland Eils^{2,5,18,19}, Florian Kurth^{3,21,22}, Leif Sander^{3,18}, Christine Goffinet^{1,2}

9 **Running Title: The Role of 90K/LGALS3BP in COVID-19**

10 ¹Institute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, Charitéplatz
11 1, 10117 Berlin, Germany

12 ²Berlin Institute of Health, Berlin (BIH), Anna-Louisa-Karsch-Str. 2, 10178 Berlin, Germany

13 ³Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin
14 Berlin, Charitéplatz 1, 10117 Berlin, Germany

15 ⁴Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin,
16 Charitéplatz 1, 10117 Berlin, Germany

17 ⁵Center for Digital Health, Berlin Institute of Health (BIH) and Charité - Universitätsmedizin,
18 corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, Charitéplatz 1,
19 10117 Berlin, Germany

20 ⁶Institute of Social Medicine, Epidemiology and Health Economics, Charité -
21 Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany

22 ⁷MediaPharma SrL, I-66013 Chieti, Italy

23 ⁸Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Downing
24 St., Cambridge, CB2 3EJ, U.K.

25 ⁹German Center for Infection Research, associated partner Charité, Berlin, Germany

26 ¹⁰Institute of Clinical Epidemiology and Biometry, University of Würzburg, Josef-Schneiderstr.
27 2, 97080 Würzburg, Germany

1 ¹¹State Institute of Health, Bavarian Health and Food Safety Authority, Eggenreuther Weg 43,
2 91058 Erlangen, Germany

3 ¹²Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association (MDC),
4 Molecular Epidemiology Research Group, 13125 Berlin, Germany

5 ¹³Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association (MDC),
6 Biobank Technology Platform, 13125 Berlin, Germany

7 ¹⁴Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Core Facility Biobank,
8 10178 Berlin, Germany

9 ¹⁵Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and
10 Humboldt-Universität zu Berlin, 10117 Berlin, Germany

11 ¹⁶Department of Biochemistry, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117
12 Berlin, Germany

13 ¹⁷The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London NW11AT,
14 United Kingdom

15 ¹⁸German Center for Lung Research (DZL), 35392, Gießen, Germany

16 ¹⁹Health Data Science Unit, Heidelberg University Hospital and BioQuant, 69120 Heidelberg,
17 Germany

18 ²¹Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, 20359
19 Hamburg, Germany

20 ²²Department of Medicine, University Medical Center, 20251 Hamburg-Eppendorf, Hamburg,
21 Germany

22

23 *Corresponding author: Christine Goffinet, Institute of Virology, Campus Charité Mitte,
24 Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany

25 Phone: +49 30 450 525 489

26 e-mail: christine.goffinet@charite.de

27 Word count abstract: 146, Word count text: 3297 incl. Figure legends

1 **Abstract**

2 Glycoprotein 90K, encoded by the interferon-stimulated gene *LGALS3BP*, displays broad
3 antiviral activity. It reduces HIV-1 infectivity by interfering with Env maturation and virion
4 incorporation, and increases survival of Influenza A virus-infected mice via antiviral innate
5 immune signaling. Here, we analyzed the expression of 90K/*LGALS3BP* in 44 hospitalized
6 COVID-19 patients. 90K protein serum levels were significantly elevated in COVID-19
7 patients compared to uninfected sex- and age-matched controls. Furthermore, PBMC-
8 associated concentrations of 90K protein were overall reduced by SARS-CoV-2 infection in
9 vivo, suggesting enhanced secretion into the extracellular space. Mining of published PBMC
10 scRNA-seq datasets uncovered monocyte-specific induction of *LGALS3BP* mRNA
11 expression in COVID-19 patients. In functional assays, neither 90K overexpression in
12 susceptible cell lines nor exogenous addition of purified 90K consistently inhibited SARS-
13 CoV-2 infection. Our data suggests that 90K/*LGALS3BP* contributes to the global type I IFN
14 response during SARS-CoV-2 infection in vivo without displaying detectable antiviral
15 properties.

16

17 **Key words:** SARS-CoV-2, COVID-19, 90K, *LGALS3BP*, Mac-2-binding protein, interferon

18 **Background**

19 SARS-CoV-2 infects host cells via interaction of its spike protein with the ACE2 receptor
20 [1,2]. Therefore, the infectivity of SARS-CoV-2 particles is largely determined by the
21 characteristics of their spike protein. Antiviral strategies targeting its biosynthesis, maturation,
22 and fusion activity may be clinically beneficial. Membrane fusion-mediating viral proteins are
23 targeted by antiviral proteins expressed from interferon (IFN)-stimulated genes (ISGs). 90K
24 (gene name *LGALS3BP*) is a ubiquitously expressed cellular secreted glycoprotein with
25 multiple antiviral activities. Expression of *LGALS3BP* is stimulated by IFNs, resulting in
26 upregulated 90K serum concentrations in individuals with viral infections, including HIV-1 [3–
27 5], HCV [6,7], hantaviruses [8], and dengue virus [9]. In the context of HIV-1 infection, 90K

1 expressed in virus-producing cells inhibits proper proteolytic processing of the envelope
2 protein precursor and virion incorporation of glycoproteins, resulting in reduction of particle
3 infectivity [10]. 90K has also been suggested to inhibit virion production through inhibition of
4 HIV-1 Gag trafficking [11]. In addition, 90K activates signaling to mount a cell-intrinsic
5 antiviral profile that was essential for survival of experimental influenza virus infection in mice
6 [12]. Furthermore, secreted 90K may promote NK cell activity, CD8⁺ T-cell-mediated
7 cytotoxicity, and cytokine production [13]. Defective IFN signaling, due to inborn mutations in
8 type I IFN-mediated immunity [14] and presence of autoantibodies against type I IFN [15]
9 have been reported as risk factors for critical COVID-19. Given the IFN-stimulated manner of
10 *LGALS3BP* expression and its reported association with viral infections in vivo, including its
11 potential suitability as a prognostic marker for disease progression in HIV-1/AIDS [16], we
12 investigated the expression profile of 90K/*LGALS3BP* in specimens of COVID-19 patients
13 and uninfected individuals and probed for a potential direct antiviral role of 90K against
14 SARS-CoV-2 infection.

15

16 **Methods**

17 **COVID-19 Cohort**

18 Hospitalized COVID-19 patients' blood samples and clinical data were collected at Charité –
19 Universitätsmedizin Berlin in the context of the *PaCOVID-19 Study* [17]. Patients were
20 recruited between March and November 2020. All patients provided a positive SARS-CoV-2
21 by RT-PCR from respiratory specimens. The study was approved by the ethics committee of
22 Charité (EA2/066/20). Written informed consent was obtained from all patients or legal
23 representatives. In this work, we analyzed 44 COVID-19 patients. 42 provided serum
24 samples and 13 blood samples for peripheral blood mononuclear cell (PBMC) isolation. Most
25 patients were sampled longitudinally (Suppl. Table 1). To minimize confounding issues,
26 patients with conditions known to enhance 90K serum concentrations were excluded from
27 our study: asthma bronchiale [18], history of malignoma within the last ten years [19],

1 Hepatitis B, C, or liver cirrhosis [20], or HIV-1 [10]. Furthermore, we excluded patients with
2 acute herpes zoster as modulation of ISGs is reported in this context [21].

3 **Cells**

4 Calu-3 (ATCC HTB-55), Caco-2 (ATCC HTB-37), Vero E6 (ATCC CRL-1586), and HEK293T
5 (ATCC CRL-3216) cells were cultured in DMEM (Sigma Aldrich) with 4.5 g/L glucose,
6 supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 1% L-glutamine
7 at 37°C and 5% CO₂. HEK293T/ACE2 cells were additionally supplemented with 13 µg/ml
8 Blasticidin. Caco-2/90K cells were additionally supplemented with 10 µg/ml Puromycin.

9 PBMCs from COVID-19 patients and healthy controls from anonymized blood donors
10 were isolated from 2-3 ml EDTA whole blood. Samples were mixed 1:1 with PBS and
11 centrifuged on Pancoll (Pan Biotech) for 30 min at 200 x g. PBMCs were then washed with
12 PBS. Remaining erythrocytes were lysed with ACK-Lysis Buffer (8,29g NH₄Cl, 1g KHCO₃,
13 0,0367g EDTA, 600ml H₂O), followed by PBS washing. PBMC pellets were frozen at -20°C.

15 **Virus, Lenti- and Retroviral Particles**

16 SARS-CoV-2 strain Munich 984 (strain: SARS-CoV-2/human/DEU/BavPat2-ChVir984, NCBI
17 GenBank Acc. No. MT270112.1) was propagated on Vero E6 cells and concentrated using
18 Vivaspin® 20 concentrators (Sartorius Stedim Biotech). Virus stocks were diluted in OptiPro
19 serum-free medium supplemented with 0.5% gelatine and PBS and stored at -80°C.
20 Infectious titer was defined by plaque titration assay.

21 VSV-G-pseudotyped lentiviral vector particles encoding human 90K were generated
22 by calcium phosphate-based transfection of HEK293T cells with the packaging plasmid
23 pCMV ΔR8.91 [22], the lentiviral transfer plasmid pWPI-puro-90K-myc or pWPI puro (gift of
24 Thomas Pietschmann) and pCMV-VSV-G [23]. The plasmid pWPI-puro-90K-myc was
25 generated by standard molecular cloning. VSV-G-pseudotyped retroviral vector particles
26 encoding human ACE2 were generated by calcium phosphate-based transfection of
27 HEK293T cells with the packaging plasmid MLV gag-pol [24], the MLV-based transfer
28 plasmid pCX4bsrACE2 [25] and pCMV-VSV-G. Vector-containing supernatant was collected

1 40 and 64 hours post-transfection and subjected to ultracentrifugation through a 20%
2 sucrose cushion. Aliquots were stored at -80°C.

3 **Infection with Authentic SARS-CoV-2**

4 Calu-3, Caco-2, and HEK293T/ACE2 cells were seeded in 6-well plates at densities of 6×10^5 ,
5 3×10^5 , and 4.5×10^5 cells/ml, respectively. Cells were infected with SARS-CoV-2 (MOI 0.01).
6 Virus inoculum was removed after 1h, cells were washed with PBS and resupplied with fresh
7 medium. Where indicated, cells were pretreated with Remdesivir, and treatment was
8 continued until the end of the experiment.

9

10 **Data Presentation and Statistical Analysis**

11 Bar graphs indicate mean values and error bars indicate standard deviation. Whiskers in box
12 plots indicate minimum to maximum values. Trends over time are displayed using locally
13 weighted scatterplot smoothing (LOESS) estimates.

14 To determine statistical significance between two independent groups, we used
15 unpaired t-tests and paired t-tests when comparing cases and matched controls, assuming
16 normal distribution. To analyze data with both independent and dependent observations due
17 to longitudinal measurements of an individual, we used mixed effects models.

18 Based on scRNA-seq data we used these models to compare expression between
19 cases and controls, just as between mild cases, severe cases, and controls regarding ten
20 cell types from PBMCs and 20 cell types from respiratory samples. As we consider all
21 analyses to be exploratory, we did not adjust for multiple testing.

22 When analyzing independent observations, graphs and statistical analyses were
23 generated using *Graph Pad Prism 9.1.2*. Further statistical analyses were performed using R
24 (Ripley 2001; Pinheiro et al. 2021; Wickham et al. 2019). The code utilized for the analysis
25 will be available at https://github.com/GoffinetLab/SARS-CoV-2_90K_patient_study.

26

27 **Results**

1 **Serum 90K Concentrations are Elevated in COVID-19 Patients as Compared to Healthy**
2 **Controls**

3 We quantified 90K concentrations in 119 serum samples from 42 hospitalized COVID-19
4 patients and 42 age- and sex-matched healthy controls (NAKO). Both mean (Figure 1A) and
5 peak (Figure 1B) 90K serum concentrations were significantly higher in patients with SARS-
6 CoV-2 compared to controls (all $p < 0.0001$). Highest 90K concentrations were detected in
7 patients classified WHO 5 (WHO 3 vs. 5, $p = 0.052$ for mean 90K, $p = 0.007$ for peak 90K).
8 Analyzing all samples with respect to the sampling time point, we saw gradually decreasing
9 90K levels over time with highest levels at early infection stages (linear mixed effects model,
10 $p < 0.001$) and similar rate of decline in patients with mild and severe disease (Figure 1C).
11 Overall, patients with severe COVID-19 (WHO 5-7) had higher 90K serum concentrations
12 than patients with mild COVID-19 (WHO 3-4) when considering symptom onset (linear mixed
13 effects model $p = 0.008$).

14 To identify a potential influence of dexamethasone treatment on 90K serum levels,
15 we compared patients treated before and after introduction of dexamethasone as standard of
16 care for COVID-19 patients with oxygen supply [26]. No significant differences between both
17 groups were detectable (Suppl. Figure 1).

18 Furthermore, we analyzed possible interrelations between 90K serum concentrations,
19 viral RNA concentrations from nasopharyngeal swabs and anti-SARS-CoV-2 IgG/IgA titers
20 and found no association (Suppl. Figure 2 A,B). For demographic aspects, no sex-dependent
21 differences in 90K serum levels were noted (Suppl. Figure 2C), but we recorded higher
22 concentrations in older healthy individuals > 55 y compared to younger individuals (linear
23 mixed effects model $p = 0.027$, Suppl. Figure 2D). This difference was not observed in
24 COVID-19 patients, which displayed enhanced 90K serum concentrations irrespective of
25 age.

26

27 **PBMC-associated 90K Protein Concentrations are Reduced in the Context of SARS-**
28 **CoV-2 Infection**

1 We hypothesized that 90K serum protein originates from peripheral blood cells. Since
2 antiviral functions have been described for intra- and extracellular 90K protein, we aimed at
3 determining if SARS-CoV-2 infection in vivo increases 90K synthesis, or whether 90K
4 secretion or stability may be modulated. Therefore, we quantified cell-associated 90K protein
5 from lysed PBMCs (17 samples from 12 COVID-19 patients) and found reduced
6 concentrations in COVID-19 compared to healthy controls, regardless of disease severity
7 (linear mixed effects model, $p=0.014$, Figure 2A). This suggests an enhanced secretion or
8 extracellular stability of 90K in COVID-19 rather than an overall enhanced biosynthesis.
9 Furthermore, in contrast to serum 90K, we obtained no evidence for time-dependent
10 changes of cell-associated 90K (Figure 2B) or association with respective serum
11 concentrations in single individuals (Figure 2C).

12

13 ***LGALS3BP* mRNA Expression in PBMCs is Unaltered in COVID-19**

14 PBMCs of our COVID-19 cohort (19 samples from $n=14$ individuals) showed no upregulated
15 *LGALS3BP* mRNA expression compared to healthy controls (Figure 3A) and no time-
16 dependent expression changes (Figure 3B), as judged by qRT-PCR analysis in bulk PBMCs.

17 In summary, in our cohort of SARS-CoV-2-infected individuals, 90K protein
18 concentrations were enhanced in sera and reduced in PBMCs, while *LGALS3BP* mRNA
19 expression in PBMCs from COVID-19 patients remained unaltered as compared to healthy
20 controls.

21

22 **Single Cell RNA-sequencing Data Reveal Upregulated *LGALS3BP* mRNA Expression 23 Specifically in Monocytes, Dendritic Cells and Plasmablasts of COVID-19 Patients**

24 To identify potential cell type-specific *LGALS3BP* mRNA expression patterns in individual cell
25 types of PBMCs of COVID-19 patients that may be undetectable in our whole-PBMC
26 analysis (Figure 3), we analyzed published scRNA-seq datasets from a Dual Center Cohort

1 Study [27]. As the scRNA-seq data of both cohorts had been generated by different
2 experimental approaches, we analyzed each cohort separately.

3 In both COVID-19 cohorts, we detected an overall increase of *LGALS3BP* expression
4 in several monocyte fractions compared to healthy controls (Figure 4, Suppl. Figure 7). In
5 cohort B, *LGALS3BP* expression levels were, in addition, significantly elevated in dendritic
6 cells and plasmablasts (mixed linear regression models, $p < 0.001$). Overall, expression was
7 highest at early infection stages and decreased after symptom onset ($p < 0.01$, Figure 4,
8 Suppl. Figure 7). Interestingly, we identified low to absent *LGALS3BP* expression levels in
9 CD163^{hi} and HLA-DR^{lo} S100A^{hi} monocytes of cohort A in severe COVID-19 (Figure 4A) while
10 patients with mild COVID-19 showed elevated levels compared to controls. However, this
11 finding was not reproduced in cohort B.

12

13 **Expression of *LGALS3BP* mRNA is Not Upregulated in Respiratory Samples from** 14 **COVID-19 Patients**

15 We analyzed the expression of *LGALS3BP* in scRNA-seq data from 32 respiratory samples
16 originating from a previous scRNA-seq study [28]. In contrast to our findings in PBMCs,
17 *LGALS3BP* expression was not increased, neither in epithelial nor in immune cell types of
18 respiratory COVID-19 samples (Suppl. Figure 4).

19

20 **SARS-CoV-2 Infection Fails to Induce *LGALS3BP* Expression in Lung- or Colon-** 21 **derived Cell Lines**

22 To elucidate SARS-CoV-2's ability to induce *LGALS3BP* expression, we infected Calu-3 and
23 Caco-2 cells with authentic SARS-CoV-2. qRT-PCR revealed a transient, 3-fold and absent
24 induction of *LGALS3BP* mRNA expression, respectively (Figure 5). In line with SARS-CoV-
25 2's ability to prevent efficient recognition by cell-intrinsic innate immunity [29], no
26 upregulation of *IFIT1* mRNA, a prototypic ISG, was detectable. In contrast, treatment with
27 IFN- α 2a induced expression of *LGALS3BP* in both cell lines as expected, although to lower
28 magnitudes than *IFIT1* (Figure 5).

1

2 **Heterologous 90K Expression Mildly Inhibits SARS-CoV-2 Infection in ACE2-** 3 **expressing HEK293T Cells but Not in Caco-2 Cells**

4 To identify a potential antiviral activity of 90K, we conducted experiments in HEK293T cells
5 that are devoid of detectable 90K expression [10,30] and therefore suitable for heterologous
6 overexpression of 90K. SARS-CoV-2 RNA concentrations in the culture supernatant of
7 infected ACE2-expressing HEK293T cells were reduced 2.5-fold by expression of 90K-myc.
8 Intracellular spike and nucleocapsid expression was diminished 1.7-fold and 3.3-fold,
9 respectively (Figure 6A). Efficient 90K expression was confirmed by immunoblotting.

10 To verify these findings in a SARS-CoV-2-susceptible cell line with endogenous
11 ACE2 expression and undetectable endogenous 90K levels by immunoblotting, we stably
12 transduced Caco-2 cells with empty vector or 90K-myc. In contrast to our finding in
13 HEK293T/ACE2 cells, overexpression of 90K in Caco-2 cells neither reduced the
14 concentration of viral RNA, nor diminished the expression of nucleocapsid and spike in
15 SARS-CoV-2 producing cells (Figure 6B) while pre-treatment with the viral polymerase
16 inhibitor Remdesivir efficiently reduced viral RNA in the supernatant as well as the synthesis
17 of nucleocapsid, as expected.

18 To analyze the effect of exogenously added 90K protein on SARS-CoV-2 infection,
19 we pretreated HEK293T/ACE2 and Caco-2 cells with 90K or the D2 domain of 90K given its
20 ability to promote cell adhesion (Capone et al. 2021). Pretreatment of cells, or treatment of
21 virus stocks with purified 90K protein or D2 domain of 90K failed to modulate release and
22 infectivity of SARS-CoV-2 particles (Suppl. Figure 6).

23

24 **Discussion**

25 Our findings of upregulated 90K serum levels in COVID-19 with highest levels in severe
26 disease courses are in line with proteomic and serological findings from hospitalized COVID-
27 19 patients [31,32]. Overall reduced PBMC-associated 90K protein levels in SARS-CoV-2
28 infected individuals and, conversely, upregulated *LGALS3BP* mRNA in monocytes,

1 plasmablasts, and dendritic cells hint towards a complex, compartment- and cell type-specific
2 regulation of 90K expression in SARS-CoV-2 infection in vivo. While we hypothesize that
3 elevated serum 90K concentrations in COVID-19 originate from monocytes, our data do not
4 exclude other 90K-producing cell types as additional and/or alternative sources. Strikingly, in
5 scRNA-seq data of respiratory samples of COVID-19 patients, *LGALS3BP* mRNA expression
6 was not upregulated, illustrating the multifaceted ability of SARS-CoV-2 to antagonize or
7 evade cellular sensing machineries in productively infected cells [33,34].

8 The role of type I IFN in the context of COVID-19 has been discussed controversially
9 and may be time-dependent. On the one hand, overdriven IFN responses are thought to
10 cause severe COVID-19 [35,36]. Since *LGALS3BP* is an ISG, enhanced 90K serum levels in
11 patients with severe COVID-19 could possibly reflect exaggerated type I IFN responses. On
12 the other hand, mounting of an efficient IFN-mediated antiviral state is associated with
13 effective clearance of SARS-CoV-2 infection and milder course of the disease [37].
14 According to the latter, patients with critical COVID-19 (WHO 6, 7) within the severe disease
15 group (WHO 5-7) had a trend towards lower 90K serum levels than patients classified WHO
16 5. Similarly, some monocyte fractions of severely ill COVID-19 patients failed to show
17 enhanced *LGALS3BP* upregulation in our scRNA-seq analysis (cohort A), whereas mildly
18 affected patients displayed distinct upregulation. However, this pattern could not be
19 reproduced in cohort B, possibly due to technical differences in the scRNA-seq pipelines
20 and/or unknown clinical differences such as medication or comorbidities. Nevertheless, since
21 *LGALS3BP* is a prototypic ISG [10,38], its upregulation might be merely indicative of the
22 overall mounting of an effective antiviral gene expression program to which *LGALS3BP* is
23 part of, and does not necessarily imply that 90K is an active antiviral component of SARS-
24 CoV-2 infection.

25 In line with this idea, we failed to establish an anti-SARS-CoV-2 activity of 90K that is
26 exerted directly on SARS-CoV-2 infection. Our study challenges former results proposing
27 90K as an inhibitor of SARS-CoV-2 spike-mediated membrane fusion [32]. The latter study
28 reported impaired cell-cell membrane fusion of ACE2-positive cells expressing SARS-CoV-2

1 spike and 90K as well as reduced susceptibility of 90K-overexpressing cells to transduction
2 with lentiviral particles decorated with SARS-CoV-2 spike [39]. However, our cell culture
3 experiments with full-length SARS-CoV-2 failed to identify an inhibitory role of 90K,
4 suggesting that authentic expression, biosynthesis and exposure of SARS-CoV-2 spike on
5 virions is insensitive to restriction by this protein.

6 In summary, our study describes the expression pattern of *LGALS3BP* in COVID-19
7 at multiple levels. We propose that 90K/*LGALS3BP* contributes to the global type I IFN
8 response during SARS-CoV-2 infection in vivo without exerting direct antiviral effects
9 detectable in cell culture. Therefore, further investigations on 90K as a potential biomarker
10 and/or potential immunomodulator of SARS-CoV-2 pathogenesis are warranted.

11

12 **Acknowledgments**

13 B.A. and F.P. are supported by the Charité PhD programme. We thank all participants who
14 took part in NAKO and the staff in this research program.

15

16

1 **Author Contributions**

2 LBJ, BA, CG designed research.

3 LBJ, BA, JL, GH, JJ, MS, RG performed research.

4 LBJ, BA, JL, DP, AA, FP, RLC, LK, BM, TJ analyzed data.

5 AA, LK, TC, DN, JF, TK, TP, JJ, CC, SI, CD, VC, MR, RE, FK, LS, CG supervised

6 research, reviewed and commented on the manuscript.

7 LBJ, BA, CG wrote the paper.

8

9 **Conflicts of Interest**

10 The authors have no conflict of interest to declare.

11

12 **Funding**

13 This work was supported by funding from the German Research Foundation (Deutsche

14 Forschungsgemeinschaft, DFG) to C.G. (Collaborative Research Centre SFB900 “Microbial

15 Persistence and its Control”, Project number 158989968, project C8) and funding of Berlin

16 Institute of Health (BIH) to C.G. T.C.J. is partly funded by NIAID-NIH CEIRS contract

17 HHSN272201400008C. This project was conducted with data from the German National

18 Cohort (NAKO) (www.nako.de). NAKO is funded by the German Federal Ministry of

19 Education and Research (BMBF, project funding reference numbers: 01ER1301A/B/C and

20 01ER1511D), federal states and the Helmholtz Association with additional financial support

21 by the participating universities and the institutes of the Leibniz Association.

22

23 **Corresponding Author Contact Information**

24 Christine Goffinet, Institute of Virology, Campus Charité Mitte, Charité - Universitätsmedizin

25 Berlin, Charitéplatz 1, 10117 Berlin, Germany

26 Phone: +49 30 450 525 489, e-mail: christine.goffinet@charite.de

1 **Figure Legends**

2 **Figure 1. Serum 90K Levels are Elevated in COVID-19 Patients**

3 (A) 90K serum levels in COVID-19 compared to controls. Controls n=42, COVID-19: n=42,
4 WHO 3: n=13, WHO 4: n=12, WHO 5: n=4, WHO 6: n=6, WHO 7: n=7. Multiple ELISA
5 quantifications per patient are presented with the mean, large points indicate deceased
6 patients. Cases vs. controls $p < 0.0001$ and differences between WHO groups (reference
7 WHO 3) were assessed using linear mixed effects models.

8 (B) Peak 90K serum concentrations in COVID-19. Cohort and dot legend identical to Figure
9 1A. Paired t-test cases vs. matched controls ($p < 0.0001$), unpaired t-test WHO 3 vs. 4 $p = 0.14$,
10 3 vs. 5 $p = 0.007$, 3 vs. 6 $p = 0.006$, 3 vs. 7 $p = 0.045$.

11 (C) 90K serum concentrations over time in COVID-19 patients, \log_{10} . n=41/116
12 (individuals/time points), WHO 3-4: n=24/62, WHO 5-7: n =17/54. 1 our of 42 patients is not
13 depicted for asymptomatic disease course. Log-normalized concentrations were modeled
14 using a linear mixed effects model (marginal $R^2 = 0.21$; conditional $R^2 = 0.56$). The effects of
15 “days post symptom onset” and “WHO classification” were statistically significant ($p = 0.0004$
16 and $p = 0.008$ respectively). Regression lines are shown, with solid lines indicating the
17 predictions on the population level and dashed lines connecting subjects.

18

19 **Figure 2. PBMC-associated 90K Protein Concentrations are Reduced in COVID-19**

20 (A) 90K protein in PBMCs, one mean value per individual. Controls: n=4, COVID-19: n=12/17
21 (individuals/timepoints), WHO 3-4: n=6/6, WHO 5-7: n=6/11. Linear mixed effects model
22 (Controls vs. COVID-19) $p = 0.01$ and (WHO 3-4 vs. WHO 5-7) $p = 0.39$.

23 (B) 90K protein in PBMCs over time in COVID-19. Cohort identical to 2A. Dots show
24 individuals with a single sampling time point. Other symbols show values belonging to
25 longitudinally sampled individuals.

26 (C) 90K protein in PBMCs and sera at identical timepoints in COVID-19 (both samples taken
27 with maximum interval of 48h) n=11/16 (individuals/time points). Dot legend s. 2B.

28

1 **Figure 3. *LGALS3BP* mRNA Expression in PBMCs is Unaltered in COVID-19**

2 (A) *LGALS3BP* mRNA Expression in PBMCs. Controls: n=4, COVID-19 cohort: n=14, WHO
3 3-4: n=7 and WHO 5-7: n=7, one mean value per individual.

4 (B) *LGALS3BP* mRNA expression in PBMCs over time. Controls: n=4, COVID-19 cohort:
5 n=14/19 (individuals/time points), WHO 3-4: n=7/8, WHO 5-7: n=7/11.

6

7 **Figure 4. *LGALS3BP* mRNA Expression is Upregulated Specifically in Monocytes,
8 Dendritic Cells and Plasmablasts of COVID-19 Patients**

9 **A:** Cohort A, **B:** Cohort B

10 *LGALS3BP* log normalized mRNA expression over time. Uninfected controls (black), “mild”
11 COVID-19 (blue) and “severe” COVID-19 (red). Thick lines indicate smoothed population
12 trends based on LOESS estimate, thin lines connect subjects. Shaded areas indicate 95%
13 confidence interval (CI) for the LOESS estimate.

14 (A) CD163^{hi} monocytes control: n=19/19, mild: n=7/10, severe: n=4/6 (individuals/time
15 points), classical monocytes control: n=22/22, mild: n=6/13, severe: n=10/14, HLA-DR^{lo}
16 S100A^{hi} monocytes control: n=8/8, mild: n=4/5, severe: n=10/14, HLA-DR^{hi} CD83^{hi}
17 monocytes control: n=9/9, mild: n=6/13, severe: n=10/12, non-classical monocytes control:
18 n=22/22, mild: n=6/10, severe: n=6/13.

19 (B) Classical monocytes - control: n=13/13, mild: n=7/17, severe: n=8/20, HLA-DR^{hi} CD83^{hi}
20 monocytes - control: n=12/12, mild: n=8/22, severe: n=9/28, CD163^{hi} monocytes - control:
21 n=13/13, mild: n=8/21, severe: n=9/26, HLA-DR^{lo} S100A^{hi} monocytes control: n=13/13, mild:
22 n=8/22, severe: n=9/28, mDCs control: n=13, mild: n=8/22, severe: n=9/23, non-classical
23 monocytes - control: n=13/13, mild: n=8/22, severe: n=9/23, plasmacytoid dendritic cells
24 (pDCs) control: n=12/12, mild: n=8/21, severe: n=9/24, plasmablasts control: n=12, mild: n=
25 8/22, severe: n=9/28.

26

27 **Figure 5. SARS-CoV-2 Infection Fails to Induce *LGALS3BP* Expression in Lung- or
28 Colon-derived Cell Lines**

1 Calu-3 (A) and Caco-2 cells (B) were treated with 500 IU/ml IFN- α 2a or infected with SARS-
2 CoV-2 (MOI 0.01). Cells were harvested 2-24h after IFN- α 2a treatment or SARS-CoV-2
3 infection for *LGALS3BP* and *IFIT1* mRNA qRT-PCR. Values are normalized to mock-
4 infected, untreated cells for each timepoint. 24h post infection or IFN- α 2a treatment, cells
5 were harvested for immunoblotting.

6

7 **Figure 6. Heterologous 90K Expression Mildly Inhibits SARS-CoV-2 Infection in ACE2-**
8 **expressing HEK293T Cells but Not in Caco-2 Cells**

9 (A) SARS-CoV-2 genome equivalents from qRT-PCR after SARS-CoV-2 infection of
10 HEK293T/ACE2 cells. Cells were mock-infected or infected in the absence or presence of
11 Remdesivir. 90K-myc was expressed via transient transfection. 24 hours post SARS-CoV-2
12 infection, supernatants were harvested for quantification of SARS-CoV-2 genome
13 equivalents. Statistical significance was determined using an unpaired t-test ($p=0.007$).
14 Immunoblot of HEK293T/ACE2 cell lysates using indicated antibodies.

15 (B) SARS-CoV-2 genome equivalents from qRT-PCR and infectivity from plaque assays
16 upon SARS-CoV-2 infection of Caco-2 cells. 90K-myc expression in Caco-2 cells was
17 achieved by lentiviral transduction. 24 hours post SARS-CoV-2 infection, supernatant was
18 harvested for quantification of SARS-CoV-2 genome equivalents and released infectivity.
19 Results are derived from two to three independent experiments. Immunoblot of Caco-2 cell
20 lysates and supernatants using indicated antibodies.

21


1 References

- 2 1. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain
3 bound to the ACE2 receptor. *Nature*. **2020**; 581(7807):215–220.
- 4 2. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on
5 ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*.
6 **2020**; 181(2):271–280.e8.
- 7 3. Natoli C, Iacobelli S, Ghinelli F. Unusually high level of a tumor-associated antigen in the
8 serum of human immunodeficiency virus-seropositive individuals. *J Infect Dis*. **1991**;
9 164(3):616–617.
- 10 4. Gröschel B, Braner JJ, Funk M, et al. Elevated plasma levels of 90K (Mac-2 BP)
11 immunostimulatory glycoprotein in HIV-1-infected children. *J Clin Immunol*. **2000**;
12 20(2):117–122.
- 13 5. Iacobelli S, Natoli C, D'Egidio M, Tamburrini E, Antinori A, Ortona L. Lipoprotein 90K in
14 human immunodeficiency virus-infected patients: a further serologic marker of
15 progression. *J Infect Dis*. **1991**; 164(4):819.
- 16 6. Artini M, Natoli C, Tinari N, et al. Elevated serum levels of 90K/MAC-2 BP predict
17 unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. *J*
18 *Hepatol*. **1996**; 25(2):212–217.
- 19 7. Kittl EM, Hofmann J, Hartmann G, et al. Serum protein 90K/Mac-2BP is an independent
20 predictor of disease severity during hepatitis C virus infection. *Clin Chem Lab Med*.
21 **2000**; 38(3):205–208.
- 22 8. Hepojoki J, Strandin T, Hetzel U, et al. Acute hantavirus infection induces galectin-3-
23 binding protein. *J Gen Virol*. **2014**; 95(Pt 11):2356–2364.
- 24 9. Liu K-T, Liu Y-H, Chen Y-H, et al. Serum Galectin-9 and Galectin-3-Binding Protein in
25 Acute Dengue Virus Infection. *Int J Mol Sci [Internet]*. **2016**; 17(6). Available from:
26 <http://dx.doi.org/10.3390/ijms17060832>
- 27 10. Lodermeier V, Suhr K, Schrott N, et al. 90K, an interferon-stimulated gene product,
28 reduces the infectivity of HIV-1. *Retrovirology*. **2013**; 10:111.
- 29 11. Wang Q, Zhang X, Han Y, Wang X, Gao G. M2BP inhibits HIV-1 virion production in a
30 vimentin filaments-dependent manner. *Sci Rep*. **2016**; 6:32736.
- 31 12. Xu G, Xia Z, Deng F, et al. Inducible LGALS3BP/90K activates antiviral innate immune
32 responses by targeting TRAF6 and TRAF3 complex. *PLoS Pathog*. **2019**;
33 15(8):e1008002.
- 34 13. Ullrich A, Sures I, D'Egidio M, et al. The secreted tumor-associated antigen 90K is a
35 potent immune stimulator. *J Biol Chem*. **1994**; 269(28):18401–18407.
- 36 14. Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-
37 threatening COVID-19. *Science [Internet]*. **2020**; 370(6515). Available from:
38 <https://www.ncbi.nlm.nih.gov/pubmed/32972995>
- 39 15. Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with
40 life-threatening COVID-19. *Science [Internet]*. **2020**; 370(6515). Available from:
41 <http://dx.doi.org/10.1126/science.abd4585>


- 1 16. Natoli C, Dianzani F, Mazzotta F, et al. 90K protein: a new predictor marker of disease
2 progression in human immunodeficiency virus infection. *J Acquir Immune Defic Syndr*.
3 **1993**; 6(4):370–375.
- 4 17. Kurth F, Roennefarth M, Thibeault C, et al. Studying the pathophysiology of coronavirus
5 disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-
6 19). *Infection*. **2020**; 48(4):619–626.
- 7 18. Kalayci O, Birben E, Tinari N, Oguma T, Iacobelli S, Lilly CM. Role of 90K protein in
8 asthma and TH2-type cytokine expression. *Ann Allergy Asthma Immunol*. **2004**;
9 93(5):485–492.
- 10 19. Marchetti A, Tinari N, Buttitta F, et al. Expression of 90K (Mac-2 BP) correlates with
11 distant metastasis and predicts survival in stage I non-small cell lung cancer patients.
12 *Cancer Res*. **2002**; 62(9):2535–2539.
- 13 20. Iacovazzi PA, Trisolini A, Barletta D, Elba S, Manghisi OG, Correale M. Serum
14 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma:
15 a comparison with alpha-fetoprotein. *Clin Chem Lab Med*. **2001**; 39(10):961–965.
- 16 21. Verweij MC, Wellish M, Whitmer T, et al. Varicella Viruses Inhibit Interferon-Stimulated
17 JAK-STAT Signaling through Multiple Mechanisms. *PLoS Pathog*. **2015**;
18 11(5):e1004901.
- 19 22. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector
20 achieves efficient gene delivery in vivo. *Nat Biotechnol*. **1997**; 15(9):871–875.
- 21 23. Stewart SA, Dykxhoorn DM, Palliser D, et al. Lentivirus-delivered stable gene silencing
22 by RNAi in primary cells. *RNA*. **2003**; 9(4):493–501.
- 23 24. Bartosch B, Dubuisson J, Cosset F-L. Infectious hepatitis C virus pseudo-particles
24 containing functional E1-E2 envelope protein complexes. *J Exp Med*. **2003**; 197(5):633–
25 642.
- 26 25. Kamitani W, Narayanan K, Huang C, et al. Severe acute respiratory syndrome
27 coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA
28 degradation. *Proc Natl Acad Sci U S A*. **2006**; 103(34):12885–12890.
- 29 26. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med*. Massachusetts
30 Medical Society; **2021**; 384(8):693–704.
- 31 27. Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 Is Marked by a
32 Dysregulated Myeloid Cell Compartment. *Cell*. **2020**; 182(6):1419–1440.e23.
- 33 28. Chua RL, Lukassen S, Trump S, et al. COVID-19 severity correlates with airway
34 epithelium-immune cell interactions identified by single-cell analysis. *Nat Biotechnol*.
35 **2020**; 38(8):970–979.
- 36 29. Chiang C, Liu G, Gack MU. Viral Evasion of RIG-I-Like Receptor-Mediated Immunity
37 through Dysregulation of Ubiquitination and ISGylation. *Viruses [Internet]*. **2021**; 13(2).
38 Available from: <http://dx.doi.org/10.3390/v13020182>
- 39 30. Lodermeier V, Ssebyatika G, Passos V, et al. The Antiviral Activity of the Cellular
40 Glycoprotein LGALS3BP/90K Is Species Specific. *J Virol [Internet]*. **2018**; 92(14).
41 Available from: <http://dx.doi.org/10.1128/JVI.00226-18>
- 42 31. Messner CB, Demichev V, Wendisch D, et al. Ultra-High-Throughput Clinical Proteomics

- 1 Reveals Classifiers of COVID-19 Infection. *Cell Syst.* **2020**; 11(1):11–24.e4.
- 2 32. Gutmann C, Takov K, Burnap SA, et al. SARS-CoV-2 RNAemia and proteomic
3 trajectories inform prognostication in COVID-19 patients admitted to intensive care. *Nat*
4 *Commun.* **2021**; 12(1):3406.
- 5 33. Shemesh M, Aktepe TE, Deerain JM, et al. SARS-CoV-2 suppresses IFN β production
6 mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of
7 added interferon. *PLoS Pathog.* **2021**; 17(8):e1009800.
- 8 34. Miorin L, Kehrer T, Sanchez-Aparicio MT, et al. SARS-CoV-2 Orf6 hijacks Nup98 to
9 block STAT nuclear import and antagonize interferon signaling. *Proc Natl Acad Sci U S*
10 *A.* **2020**; 117(45):28344–28354.
- 11 35. Zhu L, Yang P, Zhao Y, et al. Single-Cell Sequencing of Peripheral Mononuclear Cells
12 Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients.
13 *Immunity.* **2020**; 53(3):685–696.e3.
- 14 36. Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in
15 severe COVID-19. *Nature.* **2020**; 584(7821):463–469.
- 16 37. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory
17 responses in severe COVID-19 patients. *Science.* **2020**; 369(6504):718–724.
- 18 38. Brakebusch C, Sures I, Jallal B, et al. Isolation and functional characterization of the
19 human 90K promoter. *Genomics.* **1999**; 57(2):268–278.
- 20 39. Mayr M, Gutmann C, Takov K, et al. SARS-CoV-2 RNAemia and proteomic biomarker
21 trajectory inform prognostication in COVID-19 patients admitted to intensive care
22 [Internet]. Research Square. 2020 [cited 2021 Dec 2]. Available from:
23 <https://www.researchsquare.com/article/rs-101592/latest>
- 24 40. WHO Ordinal Scale for clinical improvement – [Internet]. LOINC. [cited 2022 Jun 29].
25 Available from: <https://loinc.org/LL5951-0/>
- 26 41. Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell
27 data. *Cell.* **2021**; 184(13):3573–3587.e29.
- 28 42. Okba NMA, Müller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2-
29 Specific Antibody Responses in Coronavirus Disease Patients. *Emerg Infect Dis.* **2020**;
30 26(7):1478–1488.
- 31 43. Mühlemann B, Thibeault C, Hillus D, et al. Impact of dexamethasone on SARS-CoV-2
32 concentration kinetics and antibody response in hospitalized COVID-19 patients: results
33 from a prospective observational study. *Clin Microbiol Infect.* **2021**; 27(10):1520.e7–
34 1520.e10.
- 35 44. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV)
36 by real-time RT-PCR. *Euro Surveill* [Internet]. **2020**; 25(3). Available from:
37 <http://dx.doi.org/10.2807/1560-7917.ES.2020.25.3.2000045>
- 38 45. Jones TC, Biele G, Mühlemann B, et al. Estimating infectiousness throughout SARS-
39 CoV-2 infection course. *Science* [Internet]. **2021**; 373(6551). Available from:
40 <http://dx.doi.org/10.1126/science.abi5273>

A



B



C







Figure 1. Serum 90K Levels are Elevated in COVID-19 Patients

(A) 90K serum levels in COVID-19 compared to controls. Controls n=42, COVID-19: n=42, WHO 3: n=13, WHO 4: n=12, WHO 5: n=4, WHO 6: n=6, WHO 7: n=7. Multiple ELISA quantifications per patient are presented with the mean, large points indicate deceased patients. Cases vs. controls $p < 0.0001$ and differences between WHO groups (reference WHO 3) were assessed using linear mixed effects models.

(B) Peak 90K serum concentrations in COVID-19. Cohort and dot legend identical to Figure 1A. Paired t-test cases vs. matched controls ($p < 0.0001$), unpaired t-test WHO 3 vs. 4 $p = 0.14$, 3 vs. 5 $p = 0.007$, 3 vs. 6 $p = 0.006$, 3 vs. 7 $p = 0.045$.

(C) 90K serum concentrations over time in COVID-19 patients, \log_{10} . n=41/116 (individuals/time points), WHO 3-4: n=24/62, WHO 5-7: n = 17/54. 1 out of 42 patients is not depicted for asymptomatic disease course. Log-normalized concentrations were modeled using a linear mixed effects model (marginal $R^2 = 0.21$; conditional $R^2 = 0.56$). The effects of “days post symptom onset” and “WHO classification” were statistically significant ($p = 0.0004$ and $p = 0.008$ respectively). Regression lines are shown, with solid lines indicating the predictions on the population level and dashed lines connecting subjects.



medRxiv preprint doi: <https://doi.org/10.1101/2022.07.18.22277255>; this version posted July 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).


Figure 2. PBMC-associated 90K Protein Concentrations are Reduced in COVID-19

(A) 90K protein in PBMCs, one mean value per individual. Controls: n=4, COVID-19: n=12/17 (individuals/timepoints), WHO 3-4: n=6/6, WHO 5-7: n=6/11. Linear mixed effects model (Controls vs. COVID-19) p=0.01 and (WHO 3-4 vs. WHO 5-7) p=0.39.


(B) 90K protein in PBMCs over time in COVID-19. Cohort identical to 2A. Dots show individuals with a single sampling time point. Other symbols show values belonging to longitudinally sampled individuals.

(C) 90K protein in PBMCs and sera at identical timepoints in COVID-19 (both samples taken with maximum interval of 48h) n=11/16 (individuals/time points). Dot legend s. 2B.

A



B



medRxiv preprint doi: <https://doi.org/10.1101/2022.07.18.22277255>; this version posted July 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).

Figure 3. *LGALS3BP* mRNA Expression in PBMCs is Unaltered in COVID-19


(A) *LGALS3BP* mRNA Expression in PBMCs. Controls: n=4, COVID-19 cohort: n=14, WHO 3-4: n=7 and WHO 5-7: n=7, one mean value per individual.

(B) *LGALS3BP* mRNA expression in PBMCs over time. Controls: n=4, COVID-19 cohort: n=14/19 (individuals/time points), WHO 3-4: n=7/8, WHO 5-7: n=7/11.

A

● control
 ● mild
 ● severe

LGALS3BP log normalized mRNA expression

**B**

LGALS3BP log normalized mRNA expression




Figure 4. *LGALS3BP* mRNA Expression is Upregulated Specifically in Monocytes, Dendritic Cells and Plasmablasts of COVID-19 Patients

A: Cohort A, **B:** Cohort B

LGALS3BP log normalized mRNA expression over time. Uninfected controls (black), “mild” COVID-19 (blue) and “severe” COVID-19 (red). Thick lines indicate smoothed population trends based on LOESS estimate, thin lines connect subjects. Shaded areas indicate 95% confidence interval (CI) for the LOESS estimate.

(A) CD163^{hi} monocytes control: n=19/19, mild: n=7/10, severe: n=4/6 (individuals/time points), classical monocytes control: n=22/22, mild: n=6/13, severe: n=10/14, HLA-DR^{lo} S100A^{hi} monocytes control: n=8/8, mild: n=4/5, severe: n=10/14, HLA-DR^{hi} CD83^{hi} monocytes control: n=9/9, mild: n=6/13, severe: n=10/12, non-classical monocytes control: n=22/22, mild: n=6/10, severe: n=6/13.

(B) Classical monocytes - control: n=13/13, mild: n=7/17, severe: n=8/20, HLA-DR^{hi} CD83^{hi} monocytes - control: n=12/12, mild: n=8/22, severe: n=9/28, CD163^{hi} monocytes - control: n=13/13, mild: n=8/21, severe: n=9/26, HLA-DR^{lo} S100A^{hi} monocytes control: n=13/13, mild: n=8/22, severe: n=9/28, mDCs control: n=13, mild: n=8/22, severe: n=9/23, non-classical monocytes - control: n=13/13, mild: n=8/22, severe: n=9/23, plasmacytoid dendritic cells (pDCs) control: n=12/12, mild: n=8/21, severe: n=9/24, plasmablasts control: n=12, mild: n=8/22, severe: n=9/28.

Bosquillon de Jarcy *et al.*, Figure 5

medRxiv preprint doi: <https://doi.org/10.1101/2022.07.18.22277255>; this version posted July 19, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).




Figure 5. SARS-CoV-2 Infection Fails to Induce *LGALS3BP* Expression in Lung- or Colon-derived Cell Lines

Calu-3 (A) and Caco-2 cells (B) were treated with 500 IU/ml IFN- α 2a or infected with SARS-CoV-2 (MOI 0.01). Cells were harvested 2-24h after IFN- α 2a treatment or SARS-CoV-2 infection for *LGALS3BP* and *IFIT1* mRNA qRT-PCR. Values are normalized to mock-infected, untreated cells for each timepoint. 24h post infection or IFN- α 2a treatment, cells were harvested for immunoblotting.





A**B**

Figure 6. Heterologous 90K Expression Mildly Inhibits SARS-CoV-2 Infection in ACE2-expressing HEK293T Cells but Not in Caco-2 Cells

(A) SARS-CoV-2 genome equivalents from qRT-PCR after SARS-CoV-2 infection of HEK293T/ACE2 cells. Cells were mock-infected or infected in the absence or presence of Remdesivir. 90K-myc was expressed via transient transfection. 24 hours post SARS-CoV-2 infection, supernatants were harvested for quantification of SARS-CoV-2 genome equivalents. Statistical significance was determined using an unpaired t-test ($p=0.007$). Immunoblot of HEK293T/ACE2 cell lysates using indicated antibodies.

(B) SARS-CoV-2 genome equivalents from qRT-PCR and infectivity from plaque assays upon SARS-CoV-2 infection of Caco-2 cells. 90K-myc expression in Caco-2 cells was achieved by lentiviral transduction. 24 hours post SARS-CoV-2 infection, supernatant was harvested for quantification of SARS-CoV-2 genome equivalents and released infectivity. Results are derived from two to three independent experiments. Immunoblot of Caco-2 cell lysates and supernatants using indicated antibodies.